XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Segment reporting
 12 Months Ended
Jul. 31, 2020
Segment Reporting [Abstract]  
Segment reporting

Note 17 - Segment reporting


The Company has three reportable segments: Products, Clinical Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments.


Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal and related expenses specific to other segments’ activities are allocated to those segments.


Legal settlements, net, represent activities for which royalties would have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.


The following financial information represents the operating results of the reportable segments of the Company:


Year ended July 31, 2020


   Clinical
Laboratory Services		   Life
Sciences Products		   Therapeutics   Other   Consolidated 
Revenues – Services and Products  $47,964   $26,561    —    —   $74,525 
Grant income   1,496    —    —    —    1,496 
Total   49,460    26,561    —    —    76,021 
Operating costs and expenses::                         
Cost of revenues   38,855    13,396    —    —    52,251 
Research and development   1,509    2,190   $749    —    4,448 
Selling, general and administrative   23,533    10,485    —   $8,942    42,960 
Legal and related expenses   211    2    —    6,516    6,729 
Total operating costs and expenses   64,108    26,073    749    15,458    106,388 
                          
Operating (loss) income   (14,648)   488    (749)   (15,458)   (30,367)
                          
Other income (expense)                         
Interest   (36)   56    —    434    454 
Other   45    13    —    430    488 
Foreign exchange gain   —    905    —    —    905 
(Loss) income before taxes  $(14,639)  $1,462   $(749)  $(14,594)  $(28,520)
                          
Depreciation and amortization included above  $1,553   $964    —   $263   $2,780 
                          
Share-based compensation included  above:                         
Selling, general and administrative   57    74    —    756    887 
Cost of sales   46    —    —    —    46 
Total  $103   $74    —   $756   $933 
                          
Capital expenditures  $1,811   $322    —   $37   $2,170 

The following financial information represents the operating results of the reportable segments of the Company:


Year ended July 31, 2019


   Clinical
Laboratory Services		   Life
Sciences Products		   Therapeutics   Other   Consolidated 
Revenues  $51,115   $30,055   $—   $—   $81,170 
Operating costs, expenses and legal settlements, net:                         
Cost of revenues   44,226    13,696    —    —    57,922 
Research and development   31    2,257    887    —    3,175 
Selling, general and administrative   24,230    11,860    —    8,175    44,265 
Legal and related expenses   159    27    —    2,814    3,000 
Legal settlements, net   —    (28,925)   —    —    (28,925)
Total operating costs, expenses and legal settlements, net   68,646    (1,085)   887    10,989    79,437 
                          
Operating income (loss)   (17,531)   31,140    (887)   (10,989)   1,733 
                          
Other income (expense)                         
Interest   (64)   67    —    1,053    1,056 
Other   16    2    —    364    382 
Foreign exchange loss   —    (682)   —    —    (682)
Income (loss) before taxes  $(17,579)  $30,527   $(887)  $(9,572)  $2,489 
                          
Depreciation and amortization included above  $1,625   $1,221   $—   $190   $3,036 
                          
Share-based compensation included  above:                         
Selling, general and administrative   147    95    —   $697    939 
Total  $147   $95   $—   $697   $939 
                          
Capital expenditures  $1,374   $605   $—   $6,147   $8,126 

The following financial information represents the operating results of the reportable segments of the Company:


Year ended July 31, 2018


   Clinical
Laboratory Services		   Life
Sciences Products		   Therapeutics   Other   Consolidated 
Revenues  $71,077   $29,936   $—   $—   $101,013 
Operating costs and expenses:                         
Cost of revenues   46,008    14,377    —    —    60,385 
Research and development   —    2,305    905    —    3,210 
Selling, general and administrative   24,656    11,617    —    8,182    44,455 
Legal and related expenses   67    58    —    5,002    5,127 
Total operating costs and expenses   70,731    28,357    905    13,184    113,177 
                          
Operating income (loss)   346    1,579    (905)   (13,184)   (12,164)
                          
Other income (expense)                         
Interest   (91)   50    —    894    853 
Other   29    11    —    128    168 
Foreign exchange loss   —    (275)   —    —    (275)
Income (loss) before taxes  $284   $1,365   $(905)  $(12,162)  $(11,418)
                          
Depreciation and amortization included above  $1,667   $1,387   $—   $76   $3,130 
                          
Share-based compensation included in above:                         
Selling, general and administrative   125    79    —   $609    813 
Total  $125   $79   $—   $609   $813 
                          
Capital expenditures  $1,685   $203   $—   $—   $1,888 

Geographic financial information is as follows:


Net Services, Products and Grant and royalty revenues from unaffiliated customers, Year ended July 31,:  2020   2019   2018 
United States  $64,040   $68,081   $87,296 
Switzerland   608    820    829 
United Kingdom   1,189    1,642    1,494 
Other international countries   10,184    10,627    11,394 
Total  $76,021   $81,170   $101,013 
                

Long-lived assets, at July 31,  2020   2019 
United States  $41,946   $22,057 
Switzerland   352    376 
United Kingdom   23    64 
Other international countries   67    96 
Total  $42,388   $22,593 

The Company’s reportable segments are determined based on the services they perform, the products they sell, and the royalties and license fee income they earn, not on the geographic area in which they operate. The Company’s Clinical Laboratory Services segment operates 100% in the United States with all revenue derived there. The Life Sciences Products segment earns product revenue both in the United States and foreign countries and royalty and license fee income in the United States. The following is a summary of the Life Sciences Products segment product and royalty revenues attributable to customers located in the United States and foreign countries for the years ended July 31,:


   2020   2019   2018 
United States  $14,580   $16,966   $16,220 
Foreign countries   11,981    13,089    13,716 
   $26,561   $30,055   $29,936